ES2291197T3 - Analogos de flint resistentes a proteasas. - Google Patents

Analogos de flint resistentes a proteasas. Download PDF

Info

Publication number
ES2291197T3
ES2291197T3 ES00916264T ES00916264T ES2291197T3 ES 2291197 T3 ES2291197 T3 ES 2291197T3 ES 00916264 T ES00916264 T ES 00916264T ES 00916264 T ES00916264 T ES 00916264T ES 2291197 T3 ES2291197 T3 ES 2291197T3
Authority
ES
Spain
Prior art keywords
flint
seq
baselineskip
analog
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00916264T
Other languages
English (en)
Spanish (es)
Inventor
Radmila Micanovic
Radhakrishnan Rathnachalam
Derrick Ryan Witcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2291197T3 publication Critical patent/ES2291197T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
ES00916264T 1999-03-30 2000-03-20 Analogos de flint resistentes a proteasas. Expired - Lifetime ES2291197T3 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US12683999P 1999-03-30 1999-03-30
US126839P 1999-03-30
US14007399P 1999-06-21 1999-06-21
US140073P 1999-06-21
US14707199P 1999-08-04 1999-08-04
US147071P 1999-08-04
US16052499P 1999-10-20 1999-10-20
US160524P 1999-10-20
US16066999P 1999-10-21 1999-10-21
US160669P 1999-10-21
US17274499P 1999-12-20 1999-12-20
US172744P 1999-12-20
US17818400P 2000-01-26 2000-01-26
US178184P 2000-01-26
PCT/US2000/006418 WO2000058466A2 (en) 1999-03-30 2000-03-20 Protease resistant flint analogs

Publications (1)

Publication Number Publication Date
ES2291197T3 true ES2291197T3 (es) 2008-03-01

Family

ID=27568834

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00916264T Expired - Lifetime ES2291197T3 (es) 1999-03-30 2000-03-20 Analogos de flint resistentes a proteasas.

Country Status (8)

Country Link
EP (1) EP1165781B1 (cg-RX-API-DMAC7.html)
JP (1) JP4590504B2 (cg-RX-API-DMAC7.html)
AT (1) ATE371737T1 (cg-RX-API-DMAC7.html)
AU (1) AU3739500A (cg-RX-API-DMAC7.html)
CA (1) CA2368767C (cg-RX-API-DMAC7.html)
DE (1) DE60036199T2 (cg-RX-API-DMAC7.html)
ES (1) ES2291197T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000058466A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
CA2368760A1 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Flint polypeptide analogs
AU1189101A (en) * 1999-10-20 2001-04-30 Eli Lilly And Company Therapeutic applications of flint polypeptides
WO2002060947A2 (en) * 2001-02-01 2002-08-08 Eli Lilly And Company Glycoforms a fas ligand inhibitory protein analog
JP2005506282A (ja) * 2001-02-01 2005-03-03 イーライ・リリー・アンド・カンパニー Flintグリコフォーム
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) * 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
HUP0102067A2 (hu) * 1998-03-30 2001-10-28 Eli Lilly And Co. A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai

Also Published As

Publication number Publication date
AU3739500A (en) 2000-10-16
CA2368767A1 (en) 2000-10-05
CA2368767C (en) 2008-12-30
JP4590504B2 (ja) 2010-12-01
ATE371737T1 (de) 2007-09-15
EP1165781A2 (en) 2002-01-02
DE60036199T2 (de) 2008-05-21
EP1165781B1 (en) 2007-08-29
WO2000058466A3 (en) 2001-01-11
WO2000058466A2 (en) 2000-10-05
DE60036199D1 (de) 2007-10-11
JP2002539829A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
JP5132008B2 (ja) 血管内皮増殖因子2
JP5366161B2 (ja) Tnfアンタゴニスト及びそれを有効成分とするtnf阻害剤
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
ES2364086T3 (es) Receptor de citoquina humana.
WO2023016559A1 (zh) 一类靶向pd-l1的超高亲和力小蛋白及用途
US20030082725A1 (en) DNA encoding a novel human inhibitor-of-apoptosis protein
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
US6759211B1 (en) Tumor growth inhibition- and apoptosis-associated genes and polypeptides and methods of use thereof
JP2002530062A (ja) 12個のヒト分泌タンパク質
JP4590504B2 (ja) プロテアーゼ耐性flint類似体
ES2397327T3 (es) Compuestos asociados a un dominio único de TDF y análogos de los mismos
JP2002540763A (ja) 33個のヒト分泌タンパク質
DK2657252T3 (en) MODIFIED HUMAN TUMOR CANCER FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD OF PRODUCING THEREOF
CA2368760A1 (en) Flint polypeptide analogs
US6835814B1 (en) Protease resistant flint analogs
JPWO1999014325A1 (ja) 新規Fasリガンド誘導体
US20100056441A1 (en) Method for Inhibiting Angiogenesis
AU2008256550B2 (en) VEGF-D mutants and their use
WO2023108666A1 (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
CA2613320A1 (en) Lefty, lefty derivatives and uses thereof
US6965012B1 (en) Flint polypeptide analogs
US7070957B2 (en) STARS—a muscle-specific actin-binding protein
EP1531845A2 (en) Inhibitors for use in hemostasis
EP1020521A1 (en) Fas Ligand inhibitor ( FLINT ) compositions and uses thereof
JP2002534112A (ja) 骨髄特異的タンパク質